Recent advances in the application of genetic and epigenetic modalities in the improvement of antibody-producing cell lines

Baghini S.S.; Razeghian E.; Malayer S.K.; Pecho R.D.C.; Obaid M.; Awfi Z.S.; Zainab H.A.; Shamsara M. · International Immunopharmacology (2023) · DOI: 10.1016/j.intimp.2023.110724

Resumen

There are numerous applications for recombinant antibodies (rAbs) in biological and toxicological research. Monoclonal antibodies are synthesized using genetic engineering and other related processes involved in the generation of rAbs. Because they can identify specific antigenic sites on practically any molecule, including medicines, hormones, microbial antigens, and cell receptors, rAbs are particularly useful in scientific research. The key benefits of rAbs are improved repeatability, control, and consistency, shorter manufacturing times than with hybridoma technology, an easier transition from one format of antibody to another, and an animal-free process. The engineering of the host cell has recently been developed method for enhancing the production efficiency and improving the quality of antibodies from mammalian cell lines. In this light, genetic engineering is mostly utilized to manage cellular chaperones, decrease cell death, increase cell viability, change the microRNAs (miRNAs) pattern in mammalian cells, and glycoengineered cell lines. Here, we shed light on how genetic engineering can be used therapeutically to produce antibodies at higher levels with greater potency and effectiveness.

Instituciones: Universidad San Ignacio de Loyola